# A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension

> **NCT04525885** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 161 (actual)

## Conditions studied

- Chronic Cough

## Interventions

- **DRUG:** Gefapixant 45 mg twice daily (BID)
- **DRUG:** Gefapixant 15 mg BID
- **DRUG:** Placebo
- **DRUG:** Gefapixant 45 mg BID

## Key facts

- **NCT ID:** NCT04525885
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-17
- **Primary completion:** 2022-09-15
- **Final completion:** 2022-09-15
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2024-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04525885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04525885, "A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04525885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*